General AML

Courtney DiNardo | ASCO 2018 | Venetoclax plus HMAs in elderly AML patients


Courtney DiNardo from the MD Anderson Cancer Center discusses preliminary data from a phase Ib study (NCT02203773), which is assessing the safety and efficacy of venetoclax in combination with decitabine or azacitidine in previously untreated older acute myeloid leukemia (AML) patients who are ineligible for standard induction therapy.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF